6.92
0.14%
-0.010
Lipocine Inc stock is currently priced at $6.92, with a 24-hour trading volume of 7,521.
It has seen a -0.14% decreased in the last 24 hours and a +49.78% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.87 pivot point. If it approaches the $7.06 resistance level, significant changes may occur.
Previous Close:
$6.93
Open:
$6.9478
24h Volume:
7,521
Market Cap:
$37.01M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-2.9076
EPS:
-2.38
Net Cash Flow:
$-11.88M
1W Performance:
+0.44%
1M Performance:
+49.78%
6M Performance:
+187.14%
1Y Performance:
+49.46%
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
Dec-08-17 | Resumed | H.C. Wainwright | Buy |
Oct-07-16 | Initiated | H.C. Wainwright | Buy |
Jul-22-15 | Initiated | ROTH Capital | Buy |
Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Long Term Trading Analysis for (LPCN) - Stock Traders Daily
Stock Traders Daily
Here's Why Momentum in Lipocine (LPCN) Should Keep going - Yahoo Finance
Yahoo Finance
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 - Nasdaq
Nasdaq
Is Lipocine (NASDAQ:LPCN) A Risky Investment? - Yahoo News Australia
Yahoo News Australia
Long Term Trading Analysis for (LPCN) - Stock Traders Daily
Stock Traders Daily
Why Lipocine Inc.'s (NASDAQ:LPCN) CEO Pay Matters To You - Yahoo New Zealand News
Yahoo New Zealand News
Lipocine Inc Stock (LPCN) Financials Data
Lipocine Inc (LPCN) Net Income 2024
LPCN net income (TTM) was -$16.35 million for the quarter ending December 31, 2023, a -51.99% decrease year-over-year.
Lipocine Inc (LPCN) Cash Flow 2024
LPCN recorded a free cash flow (TTM) of -$11.88 million for the quarter ending December 31, 2023, a +1.85% increase year-over-year.
Lipocine Inc (LPCN) Earnings per Share 2024
LPCN earnings per share (TTM) was -$3.05 for the quarter ending December 31, 2023, a -36.16% decline year-over-year.
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Cap:
|
Volume (24h):